Pancreatic-enzyme Replacement Therapy With Pancreaze (Pancrelipase) Delayed-release in Addition to Standard of Care for Borderline Resectable, Locally Advanced, and Advanced Pancreatic Adenocarcinoma Patients (PANCAX-3) With Cachexia and Exocrine Pancreatic Insufficiency
Latest Information Update: 04 Jun 2025
At a glance
- Drugs Pancrelipase (Primary)
- Indications Cachexia; Exocrine pancreatic insufficiency
- Focus Therapeutic Use
- Acronyms PANCAX-3
Most Recent Events
- 04 Jun 2025 Last checked against ClinicalTrials.gov record.
- 07 Mar 2025 Planned End Date changed from 1 Dec 2025 to 1 Jan 2027.
- 07 Mar 2025 Status changed from recruiting to active, no longer recruiting.